Updated:
Tissue Regenix Ltd
Tissue Regenix Group is a pioneering, international medical technology company, focusing on the development of regenerative productsAbout Us Our vision is to…
Tissue Regenix Ltd
Tissue Regenix Group is a pioneering, international medical technology company, focusing on the development of regenerative productsAbout Us Our vision is to…
General information
Firm type
Asset Manager
Location
Region
Europe
Country
United Kingdom
City
Leeds
Corporate office
Leeds, United Kingdom
Additional offices
San Antonio, Texas, United States
Sector focus
Frequently asked questions
What are Tissue Regenix's two core technology platforms?
Tissue Regenix uses dCELL for decellularizing soft tissue and BioRinse for sterilizing bone allografts. These platforms are designed to reduce immune rejection and support natural tissue regeneration (per the firm's website).
What are Tissue Regenix's flagship products?
Flagship products include DermaPure (soft tissue matrix), ConCelltrate (bone graft), OrthoPure XT (ligament reconstruction implant, not available in the US), and AmnioWorks (birth tissue products). They target orthopaedics, sports medicine, dental, ophthalmology, wound care, urology/gynaecology, and cardiac surgery.
Does Tissue Regenix operate in the US?
Yes. The company's San Antonio, Texas facility processes, stores, and distributes human cells, tissues, and cellular- and tissue-based products (HCT/P) in compliance with FDA and AATB standards. It is AATB-accredited and FDA-registered.
What is OrthoPure XT and where is it available?
OrthoPure XT is a porcine-derived ligament reconstruction implant based on the dCELL technology. It is designed to provide a biomechanically appropriate scaffold for cellular repopulation. The company notes that this product is not available in the United States.
How does Tissue Regenix ensure quality and regulatory compliance?
The Leeds facility operates under ISO 13485:2016 certification. The San Antonio facility complies with FDA, AATB, and state regulations. Both sites follow applicable standards for medical device manufacturing and tissue banking.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: